Cost SavingsHL TH delivered $200M in annualized run rate cost savings for 2023, surpassing its $150M goal.
Earnings4Q revenue of $18.8M was above expectations and the previous guidance range, driven by strong pull-through from the Cue Reader installed base and ongoing Cue Integrated Care platform adoption.
LeadershipThe appointment of Dr. Paul Brown, the former CEO of Roche Molecular Diagnostics, as a strategic advisor could provide valuable insight and experience.